#eli-lilly

[ follow ]
#novo-nordisk

Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions

Many patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.

Novo Nordisk's Wegovy sales jump on international rollouts

Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.

Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug

Shares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.

Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions

Many patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.

Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trial

Novo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.

Novo Nordisk's Wegovy sales jump on international rollouts

Wegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.

Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug

Shares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.
morenovo-nordisk
#stock-market

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen 464.44% since 2020, indicating strong growth potential and key clinical advancements shaping its future.
With a focus on research in oncology and diabetes prevention, Eli Lilly is well-positioned for sustained growth in the coming years.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has seen remarkable growth recently, with a projected positive future driven by innovations and strategic investments.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has experienced significant growth, indicating strong market confidence and potential for future stock splits.
Investors should focus on projected revenue and innovations rather than solely on past performance when evaluating Eli Lilly's future.

Has Eli Lilly Destroyed Hims & Hers Upside?

Hims & Hers Health capitalized on weight-loss drug market trends while facing new competition from Eli Lilly's FDA-approved product offerings.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen dramatically over recent years, showcasing strong market confidence and growth potential.
Future projections for Eli Lilly's earnings and drug performance indicate significant growth opportunities despite recent safety concerns.

Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro

Eli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen 464.44% since 2020, indicating strong growth potential and key clinical advancements shaping its future.
With a focus on research in oncology and diabetes prevention, Eli Lilly is well-positioned for sustained growth in the coming years.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has seen remarkable growth recently, with a projected positive future driven by innovations and strategic investments.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has experienced significant growth, indicating strong market confidence and potential for future stock splits.
Investors should focus on projected revenue and innovations rather than solely on past performance when evaluating Eli Lilly's future.

Has Eli Lilly Destroyed Hims & Hers Upside?

Hims & Hers Health capitalized on weight-loss drug market trends while facing new competition from Eli Lilly's FDA-approved product offerings.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock has risen dramatically over recent years, showcasing strong market confidence and growth potential.
Future projections for Eli Lilly's earnings and drug performance indicate significant growth opportunities despite recent safety concerns.

Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro

Eli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.
morestock-market
#zepbound

Eli Lilly to sell Zepbound directly to consumers without insurance coverage

Eli Lilly will sell weight loss drug Zepbound directly to consumers via LillyDirect, offering an affordable option for those without insurance.

F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Eli Lilly slashes prices of weight-loss drug Zepbound for single-use vials

Eli Lilly is introducing lower-cost single-use vials of Zepbound to meet demand and improve accessibility for weight-loss medications.

Lilly sells Zepbound vials at 50% discount to meet weight loss drug demand

Eli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.

Eli Lilly just halved the price of its weight-loss drug - declaring war on the booming market of knock-offs

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly just made its weight-loss drug cheaper with a simple design tweak

Eli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.

Eli Lilly to sell Zepbound directly to consumers without insurance coverage

Eli Lilly will sell weight loss drug Zepbound directly to consumers via LillyDirect, offering an affordable option for those without insurance.

F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Eli Lilly slashes prices of weight-loss drug Zepbound for single-use vials

Eli Lilly is introducing lower-cost single-use vials of Zepbound to meet demand and improve accessibility for weight-loss medications.

Lilly sells Zepbound vials at 50% discount to meet weight loss drug demand

Eli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.

Eli Lilly just halved the price of its weight-loss drug - declaring war on the booming market of knock-offs

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly just made its weight-loss drug cheaper with a simple design tweak

Eli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.
morezepbound
#weight-loss-drugs

Unemployed to be given weight-loss jab to help them back into work, government says

Eli Lilly invests £279 million in UK's life sciences for weight-loss jab trials aimed at reducing unemployment and health burdens.

Could weight loss drugs fix UK's unemployment problem?

Eli Lilly is testing weight-loss drugs in the UK to see if they can help reduce unemployment rates by getting people back to work.

Unemployed to be given weight-loss jab to help them back into work, government says

Eli Lilly invests £279 million in UK's life sciences for weight-loss jab trials aimed at reducing unemployment and health burdens.

Could weight loss drugs fix UK's unemployment problem?

Eli Lilly is testing weight-loss drugs in the UK to see if they can help reduce unemployment rates by getting people back to work.
moreweight-loss-drugs
#fda

Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals

The FDA's decision to change a prior ruling alleviated patient access issues but raised safety concerns regarding compounded drugs.

Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over

Hims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.

Lilly weight-loss drug copycats dealt blow as shortage ends

Eli Lilly's medications are no longer in shortage, affecting the market for knockoff versions.
The FDA has resolved the shortage of Zepbound and Mounjaro, impacting compounded alternatives.

Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals

The FDA's decision to change a prior ruling alleviated patient access issues but raised safety concerns regarding compounded drugs.

Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is over

Hims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.

Lilly weight-loss drug copycats dealt blow as shortage ends

Eli Lilly's medications are no longer in shortage, affecting the market for knockoff versions.
The FDA has resolved the shortage of Zepbound and Mounjaro, impacting compounded alternatives.
morefda

The 3 Top Pharma Stocks to Buy in September 2024

Pharma stocks are revitalizing investors' interest, propelled by new growth catalysts and innovative drugs.
Eli Lilly stands out with significant stock price growth and effective diabetes and weight loss drug launches.

Prediction: This Will Be the Biggest Pharma Stock in 10 Years

Pharmaceutical stocks are relatively stable during economic downturns, appealing to long-term investors despite drug pricing concerns.
#tirzepatide

Taking Mounjaro Reduces Risk of Developing Diabetes by 94 Percent in Three-Year Trial

Lilly's weight loss injectables Zepbound and Mounjaro significantly reduce diabetes risk, showing lasting effects even after treatment ends.

Eli Lilly Blasts Use of Mounjaro and Zepbound for "Cosmetic Weight Loss"

Pharmaceutical company Eli Lilly is warning against off-label use of its weight loss medications.

Taking Mounjaro Reduces Risk of Developing Diabetes by 94 Percent in Three-Year Trial

Lilly's weight loss injectables Zepbound and Mounjaro significantly reduce diabetes risk, showing lasting effects even after treatment ends.

Eli Lilly Blasts Use of Mounjaro and Zepbound for "Cosmetic Weight Loss"

Pharmaceutical company Eli Lilly is warning against off-label use of its weight loss medications.
moretirzepatide

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Eli Lilly's stock price skyrocketed due to investor sentiment on future drug pipeline potential, with projections for further growth from 2025 to 2030.
#fda-approval

Alzheimer's drug that can slow disease gets backing from FDA advisers

FDA advisers backed Alzheimer's drug from Eli Lilly, suggesting approval for mild dementia treatment.

FDA approves new Alzheimer's treatment, donanemab from Eli Lilly

The FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.

New Drug Approved for Early Alzheimer's

FDA approved new Alzheimer's drug Kisunla by Eli Lilly, showing potential cognitive decline slowing and unique stoppage after amyloid clearance.

Alzheimer's drug that can slow disease gets backing from FDA advisers

FDA advisers backed Alzheimer's drug from Eli Lilly, suggesting approval for mild dementia treatment.

FDA approves new Alzheimer's treatment, donanemab from Eli Lilly

The FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.

New Drug Approved for Early Alzheimer's

FDA approved new Alzheimer's drug Kisunla by Eli Lilly, showing potential cognitive decline slowing and unique stoppage after amyloid clearance.
morefda-approval

Eli Lilly warns about dangers of fake and counterfeit Mounjaro, Zepbound

Eli Lilly warns against fake and compounded diabetes and weight loss drugs, addresses concerns of shortages and health risks.

The Next Potential Alzheimer's Drug Clears a Big Hurdle

Drug companies are making progress in Alzheimer's treatment with FDA panel's positive evaluation of Eli Lilly's donanemab.
[ Load more ]